BRAF Inhibitors Flashcards
What drugs are in the BRAF Inhibitors class?
Drugs in this class are:
- Dabrafenib
- Vemurafenib
- Encorafenib
What is the brand name of Dabrafenib?
The brand name of this generic drug is:
- Tafinlar
What is the brand name of Vemurafenib?
The brand name of this generic drug is:
- Zelboraf
What is the brand name of Encorafenib?
The brand name of this generic drug is:
- Braftovi
What is the generic of name of Tafinlar?
The generic name of this brand name drug is:
- Dabrafenib
What is the generic of name of Zelboraf?
The generic name of this brand name drug is:
- Vemurafenib
What is the generic of name of Braftovi?
The generic name of this brand name drug is:
- Encorafenib
What are the main indications for use of Dabrafenib?
The main indications of this drug are:
- Melanoma (with BRAFV6ooE or BRAFV6ooK mutation)
- Non-small cell lung cancer (with BRAF V6ooE mutation)
- Thyroid cancer (with BRAF V6ooE mutation)
What are the main indications for use of Vemurafenib?
The main indications of this drug are:
- Melanoma (with BRAFV6ooE or BRAFV6ooK mutation)
- Non-small cell lung cancer (with BRAF V6ooE mutation)
- Erdheim-Chester disease (with BRAF V6oo mutation)
What are the main indications for use of Encorafenib?
The main indications of this drug are:
- Melanoma (with BRAFV6ooE or BRAFV6ooK mutation)
- Colorectal cancer (with BRAF V6ooE mutation)
What is the class and MOA of Dabrafenib?
This drug in the following class:
- BRAF Inhibitors
This drug’s MOA is as follows:
- Selectively targets mutated forms BRAF kinase (V600-) and interferes with the mitogen-activated protein kinase (MAPK) signaling pathway that regulates the proliferation and survival of melanoma cells.
What is the class and MOA of Vemurafenib?
This drug in the following class:
- BRAF Inhibitors
This drug’s MOA is as follows:
- Selectively targets mutated forms BRAF kinase (V600-) and interferes with the mitogen-activated protein kinase (MAPK) signaling pathway that regulates the proliferation and survival of melanoma cells.
What is the class and MOA of Encorafenib?
This drug in the following class:
- BRAF Inhibitors
This drug’s MOA is as follows:
- Selectively targets mutated forms BRAF kinase (V600-) and interferes with the mitogen-activated protein kinase (MAPK) signaling pathway that regulates the proliferation and survival of melanoma cells.
What are the notable monitoring parameters for Vemurafenib?
The notable monitoring parameters for this drug are:
- See common parameters for class
- EKG at baseline. 15 days after initiation. then monthly for 3 months. then every 3 months thereafter (more frequently if clinically appropriate) and with dosage adjustments.
What are the notable/common monitoring parameters for the BRAF Inhibitors class?
The notable/common monitoring parameters for this drug class are:
- BRAFV6ooK or V6ooE mutation status prior to treatment
- Dermatologic evaluations prior to initiation, every 2 months during therapy, and for up to 6 months following discontinuation to assess for new cutaneous malignancies